

Special thanks to:



8th SYMPOSIUM on ACUTE PROMYELOCYTIC LEUKEMIA
& SECONDA RIUNIONE NAZIONALE GIMEMA 1

8th SYMPOSIUM ON
**Acute
Promyelocytic
Leukemia**

Dedicated to the memory of Prof. Francesco Lo Coco

» April 10-11, 2024

ROMA • Hotel NH Collection Roma Centro

PROGRAM



AUSPICES

AIL – *Associazione Italiana contro le Leucemie, Linfomi e Mieloma*

SIE – *Società Italiana di Ematologia*

SIES – *Società Italiana di Ematologia Sperimentale*

FACULTY

William Arcese, *Roma*

Nancy Berliner, *Boston (USA)*

Francesca Bonifazi, *Bologna*

Massimo Breccia, *Roma*

Francesco Buccisano, *Roma*

Antonio Curti, *Bologna*

Stephane de Botton, *Villejuif (France)*

Valerio De Stefano, *Roma*

Hughes De-Thé, *Paris (France)*

Richard Dillon, *London (United Kingdom)*

Konstanze Döhner, *Ulm (Germany)*

Fabio Efficace, *Roma*

Anna Falanga, *Bergamo*

Felicetto Ferrara, *Napoli*

Luca Guarnera, *Roma*

Harry Iland, *Sydney (Australia)*

Jeroen Janssen, *Nijmegen (The Netherlands)*

Soren Lehmann, *Uppsala (Sweden)*

Jun-Min Li, *Shanghai (China)*

Franco Locatelli, *Roma*

Pau Montesinos, *Valencia (Spain)*

Fabrizio Pane, *Napoli*

Pier Giuseppe Pelicci, *Milano*

Alfonso Piciocchi, *Roma*

Uwe Platzbecker, *Dresden (Germany)*

Alessandro Rambaldi, *Bergamo*

Eduardo Rego Ribeirão, *Preto (Brasil)*

Nigel Russel, *Nottingham (United Kingdom)*

Miguel A. Sanz, *Valencia (Spain)*

Giorgina Specchia, *Bari*

Agostino Tafuri, *Roma*

Anna Maria Testi, *Roma*

Ian Thomas, *Cardiff (United Kingdom)*

Alessandro Maria Vannucchi, *Firenze*

Adriano Venditti, *Roma*

Marco Vignetti, *Roma*

Maria Teresa Voso, *Roma*

12.00 Registration & welcome lunch

12.30-13.45 SESSION I: APL BIOLOGY

Chairmen: M. Sanz, A.M. Vannucchi

What's new IN: APL biology

P.G. Pelicci

Mechanisms of treatment resistance
H. De-The'

APL Coagulopathy and bleeding complications

A. Falanga

Genotypic and phenotypic features of APL-like AML

F. Buccisano

13.45-14.45 SESSION II: UPDATES ON FRONT-LINE TREATMENT

Chairmen: K. Dohner, A. Venditti

The Harmony APL project

M.T. Voso

High-risk APL

P. Montesinos

Is disease monitoring still necessary?

R. Dillon

14.45-15.30 SESSION III: TREATMENT COMPLICATIONS

Chairmen: A. Curti, F. Pane

Early deaths: Swedish registry experience

S. Lehmann

Differentiation syndrome and others

L. Guarnera

15.30-15.45 *Coffee break*

15.45-16.30 SESSION IV: SURVIVORSHIP AND QUALITY OF LIFE IN APL

Chairmen: F. Efficace, A. Tafuri

Long-term survival and quality of life in APL patients

F. Efficace

What Next for QoL Trial Design in APL?

I. Thomas

16.30-18.00 SESSION V: ORAL COMMUNICATIONS

Chairmen: V. De Stefano, F. Ferrara

C01 - UNRAVELING COAGULOPATHY IN ACUTE PROMYELOCYTIC LEUKEMIA: INSIGHTS FROM SINGLE-CELL RNA SEQUENCING

A. Maity, S. Poonia, N. Bhattacharya, H. Jain, M. Sengar, D. Sengupta, S. K. Hasan (Mumbai-IND, New Delhi-IND)

C02 - IN-DEPTH ANALYSIS OF THE PATHOPHYSIOLOGY OF DIFFERENTIATION SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA

G. Falconi, E. Galossi, F. Lazzaroni, E. Attardi, L. Guarnera, H. Hajrullaj, T. Ottone, S. Travaglini, M. Divona, E. Fabiani, A.M. Nardoza, A. Curti, V. Martini, C. Mazzone, E. Ortu La Barbera, D. Armiento, S. Sica, G. Gianfaldoni, C. Gurnari, L. Cudillo, A. Ferrari, A. Venditti, A.M. Vannucchi, M.T. Voso (Roma, Milano, Bologna, Frosinone, Latina, Firenze, Cleveland-USA)

C03 - RISK STRATIFICATION AND EARLY DEATH PREDICTORS IN ACUTE PROMYELOCYTIC LEUKEMIA: INSIGHTS FROM A COMPREHENSIVE ANALYSIS OF SANZ RISK CATEGORIES

L. Chen, H.M. Zhu, F.Y. Dong, Y. Li, Q.F. Liu, Y. Hu, Y.C. Zhang, J. Jin, J. D. Hu, T. Liu, D.P. Wu, J.P. Chen, Y.R. Lai, J.X. Wang, J. Li, J.Y. Li, X. Du, X. Wang, M.Z. Yang, J.S. Yan, G.F. Ouyang, L. Liu, M. Hou, X.J. Huang, Y.T. Huang, R. An, W. Jin, Y.M. Zhu, J. Li, K.K. Wang, Z. Chen, S.J. Chen, J.M. Li (Shanghai-CHN, Shenyang-CHN, Guangzhou-CHN, Wuhan-CHN, Hangzhou-CHN, Quanzhou-CHN, Chengdu-CHN, Suzhou-CHN, Chongqing-CHN, Guangxi-CHN, Tianjin-CHN, Nanjing-CHN, Jinan-CHN, Hefei-CHN, Dalian-CHN, Ningbo-CHN, xi'an-CHN, Beijing-CHN)

C04 - THE ONCOGENIC Δ NP73 ISOFORM IS ASSOCIATED WITH ATRA-RESISTANCE IN APL

C. Ortiz, D. Pereira-martins, C. Thomé, G. Ferreira, T. Bianco, I. Weinhauser, L. De Almeida, V. Wagatsuma, L. Botelo, C. Silva, L. Pontes, V. Faça, G. Huls, E. Ammatuna, J.J. Schuringa, E. Rego (Ribeirão Preto-BRA, São Paulo-BRA, Groningen-NL)

C05 - LONG-TERM FOLLOW-UP OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: INSIGHT FROM A SINGLE-CENTER COHORT

A. Costa, I. Carmosino, E. Scalzulli, C. Minotti, D. Diverio, M.L. Bisegna, C. Ielo, M. Martelli, M. Breccia (Roma, Cagliari)

C06 - REAL-WORLD IMPACT OF FIRST-LINE ARSENIC TRIOXIDE ON EARLY DEATH AND LONG-TERM OUTCOMES OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA IN PORTUGAL: A MULTICENTRIC STUDY FROM THE GRUPO PORTUGUES DE LEUCEMIAS AGUDAS
J. Infante, E. Aguiar, I. Sá, I. Marques, M. Neto, C. Almeida, T. Nascimento, E. Cortesão, G. Sapinho, G. Esteves, T. Monteiro-brás, L. Regadas, I. Vieira, F. Saraiva, G. Alikhanov, J. Santos, P. Ribeiro, F. Trigo (Lisbona-PT, Porto-PT, Coimbra-PT)

Opening Ceremony and Authorities Greetings

18.00-18.45 Welcome by Prof. Nathan LeviaIdi Ghiron - Rector of University of Rome Tor Vergata

APL past and future
M. Vignetti, M.T. Voso

19.00-20.15 Welcome cocktail



08.00-09.30 SESSION VI: UPDATE IN FRONT-LINE TRIALS AND NEW DRUGS**Chairmen: N. Berliner, A. Piciocchi**

Chemo-free post-induction therapy for all APL patients

J. Li

Australasian protocols

H.J. Iland

UK protocols

N. Russell

Apollo trial

*U. Platzbecker***09.30-11.00 SESSION VII: SPECIAL SITUATIONS****Chairmen: F. Locatelli, G. Specchia**

APL in children:

ATRA + chemotherapy: results of clinical studies in childhood APL

A.M. Testi

ATO/ATRA-based treatment of childhood APL

F. Locatelli

APL in the elderly

F. Ferrara

APL in developing countries

*E. Rego***11.00-11.15** *Coffee break***11.15-12.45 SESSION VIII: TREATMENT APPROACHES AT RELAPSE****Chairmen: W. Arcese, F. Bonifazi**

Conventional and new drugs

M. Breccia

Role of autologous and allogeneic transplantation

*A. Rambaldi***13.00-13.45** *Lunch***13.45-15.45 EHA AML SWG meeting****Chairs: K. Dohner, M.T. Voso**

Clonal hematopoiesis and prediction to AML

J. Janssen

Classification and risk assessment of AML at diagnosis

K. Döhner

Treatment options for unfit elderly AML patients with focus on triplet therapies

S. De Botton

Molecular MRD monitoring in AML

*R. Dillon***15.45-16.15** Conclusions and “take home messages”*M.T. Voso***GENERAL INFORMATION****MEETING VENUE**

Hotel NH Collection Roma Centro

Via dei Gracchi, 324, 00192 Roma

REGISTRATION

Registration is free and available on

www.ercongressi.it, section “I nostri congressi/2024”.Direct link: <https://manage.ercongressi.it/event/subscription/289>**ITALIAN CME CREDITS**

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-403019
- No. 4,2 CME credits for Physicians (disciplines: Hematology, Internal Medicine, Oncology, Clinical Biochemistry, Microbiology and Virology, Clinical Pathology, Radiotherapy, Pathological Anatomy, Nuclear Medicine), Biologists, Biomedical Laboratory HealthTechnician, Nurse and Chemists.
- Educational objective: “linee guida-protocolli procedure”

OFFICIAL LANGUAGE

English

ABSTRACT BOOKAuthorized abstract will be published on the Mediterranean Journal of Hematology and Infectious Diseases and on the Abstract E-Book that will be available at www.ercongressi.it in the “I nostri eventi/2024” section.**POSTER**

Scientific submissions selected as posters will be available electronically on provided totems during the meeting.

CHAIR

M.T. Voso, M.A. Sanz

HONORARY PRESIDENTS

S. Amadori, W. Arcese

SCIENTIFIC COORDINATORS

P. Fazi, A. Piciocchi, M. Vignetti, M.T. Voso

SCIENTIFIC SECRETARIAT

M. Breccia, A.M. Cicconi, M.D. Divona, F. Efficace, A. Falanga, C. Gurnari, S. Lavorgna, T. Ottone, A.M. Testi

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy

Phone +39 051 4210559

E-mail: ercongressi@ercongressi.itwww.ercongressi.it

With the unrestricted educational grant of

abbvie

AMGEN

 NOVARTIS

 astellas


AstraZeneca 

 Bristol Myers Squibb™

Johnson & Johnson

 Roche

 Incyte | SOLVE
ON.

 Jazz Pharmaceuticals

SERVIER 
moved by you